Is ZimVie, Inc. overvalued or undervalued?

As of 10 August 2022, ZimVie, Inc. has moved from a classification of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios indicate significant concerns: the Price to Book Value stands at 0.66, while the EV to EBITDA ratio is 11.89, and the ROE is a troubling -1.76%.
In comparison to its peers, ZimVie, Inc. has a P/E ratio of -35.0723, which is worse than AngioDynamics, Inc. at -21.8992 and Sanara MedTech, Inc. at -18.7257. These figures suggest that ZimVie is underperforming relative to its competitors in the same industry. Additionally, the company's stock has seen a significant decline, with a year-to-date return of -37.99%, contrasting sharply with the S&P 500's positive return of 2.44% during the same period.